European Commissioner Joaquin Almunia has reportedly confirmed that he is “gathering information” regarding allegations that pharmaceutical giants Roche Holding and Novartis colluded to prevent the sale of an eye disease treatment in favor of selling the treatment’s more expensive counterpart.
Almunia answered reporter questions Monday and confirmed that the Commission would “assess whether further action is needed” regarding the matter, but declined to elaborate. A formal investigation has not been opened.
Italian regulators fined the companies more than $254 million in 2012 for similar allegations. Italy’ antitrust regulator sanctioned the firms after finding that the companies colluded to block eye disease medicine Avastin so a more expensive drug, Lucentis, could be sold. The companies jointly market for Lucentis.
Novartis is appealing Italy’s decision.
Almunia told reporters, however, that the case in Italy will not impact the Commission’s actions on the matter, and does not necessarily indicate similar anticompetitive conduct by the companies in other EU member states.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Regulators Set to Clear Microsoft’s $13B OpenAI Investment
Apr 17, 2024 by
CPI
Biden Pledges to Block US Steel Acquisition by Japanese Firm
Apr 17, 2024 by
CPI
Canada Targets Tech Titans with New Digital Tax in 2024
Apr 17, 2024 by
CPI
EU Privacy Watchdog Calls for Meta to Offer Ad-Free Option
Apr 17, 2024 by
CPI
Japan’s Antitrust Overhaul Targets Tech Titans Like Apple
Apr 17, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – China Edition – Year of the Dragon
Apr 16, 2024 by
CPI
Review Logic and Rules for Concentrations of Undertakings that Do Not Meet the Standard of Notification
Apr 16, 2024 by
CPI
China’s Review of Semiconductor Transactions
Apr 16, 2024 by
CPI
Key Challenges and Tips for Merger Control Filing in China for Listed Companies
Apr 16, 2024 by
CPI
Key Point Review: China SPC Antitrust Judgments in 2023
Apr 16, 2024 by
CPI